

March 21, 2025

## Naari Pharma Pvt. Ltd.: Ratings withdrawn

### Summary of rating action

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating action
Long-term – Fund-based – Term loan	34.60	34.60	[ICRA]BB+ (Stable); withdrawn
Long-term – Fund-based – Working capital limits	40.00	40.00	[ICRA]BB+ (Stable); withdrawn
Short-term – Fund-based/ Non-fund based – Working capital limits (sublimit)	(30.00)	(30.00)	[ICRA]A4+; withdrawn
<b>Total</b>	<b>74.60</b>	<b>74.60</b>	

\*Instrument details are provided in Annexure I

### Rationale

ICRA has withdrawn the rating assigned to the bank facilities of Naari Pharma Pvt. Ltd. (Naari/NPPL) at the company's request and based on the No Objection Certificate (NOC) received from the bankers, in accordance with ICRA's policy on withdrawal of credit ratings. However, ICRA does not have information to suggest that the credit risk has changed since the time the rating was last reviewed.

The key rating drivers and their description, liquidity position and rating sensitivities have not been captured as the rated instruments are being withdrawn. The previous detailed rating rationale is available at the following link: [Click here](#).

### Analytical approach

Analytical approach	Comments
Applicable rating methodologies	<a href="#">Corporate Credit Rating Methodology</a> <a href="#">Pharmaceuticals</a> <a href="#">Policy on withdrawal of Credit Ratings</a>
Parent/Group support	Standalone
Consolidation/Standalone	The ratings are based on the standalone financial statements of the rated entity.

### About the company

Naari was incorporated as Indo Phyto Chemicals Private Limited on February 23, 1978, and is currently engaged in the development, manufacture and supply of finished pharmaceutical products in female healthcare domain. Naari's formulation manufacturing facility is located at Rudrapur, India, and is involved in the development and manufacturing of hormones with capabilities across tablets. The R&D facility is recognised by Department of Scientific and Industrial Research (DSIR).

### Key financial indicators (audited)

NPPL Standalone	FY2022	FY2023	FY2024
Operating income	87.1	98.4	116.8
PAT	-0.8	-48.2	23.7
OPBDIT/OI	23.7%	29.2%	30.1%

<b>PAT/OI</b>	-0.9%	-48.9%	20.3%
<b>Total outside liabilities/Tangible net worth (times)</b>	1.2	1.9	1.2
<b>Total debt/OPBDIT (times)</b>	4.5	3.4	2.7
<b>Interest coverage (times)</b>	3.6	4.2	5.3

Source: Company, ICRA Research; All ratios as per ICRA's calculations; Amount in Rs. Crore; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

**Status of non-cooperation with previous CRA: Not applicable**

**Any other information: None**

### Rating history for past three years

Instrument	Current (FY2025)					Chronology of rating history for the past 3 years					
	Type	Amount Rated (Rs. crore)	Mar-21-2025	FY2025		FY2024		FY2023		FY2022	
				Date	Rating	Date	Rating	Date	Rating	Date	Rating
<b>Term loan</b>	Long term	34.60	[ICRA]BB+(Stable); withdrawn	Jul-12-24	[ICRA]BB+(Stable)	Oct-31-23	[ICRA]BB-; Rating watch with developing implications	Mar-14-23	[ICRA]BB-(Stable)	Apr-22-21	[ICRA]BBB-(CE) (Negative)
								Dec-29-22	[ICRA]BB-(Stable)		
								Jul-28-22	[ICRA]BB+(CE) (Stable)		
<b>Fund based – Working capital limits</b>	Long term	40.00	[ICRA]BB+(Stable); withdrawn	Jul-12-24	[ICRA]BB+(Stable)	Oct-31-23	[ICRA]BB-; Rating watch with developing implications	Mar-14-23	[ICRA]BB-(Stable)	Apr-22-21	[ICRA]BBB-(CE) (Negative)
								Dec-29-22	[ICRA]BB-(Stable)		
								Jul-28-22	[ICRA]BB+(CE) (Stable)		
<b>Fund based/ non-fund based*</b>	Short term	(30.00)	[ICRA]A4+; withdrawn	Jul-12-24	[ICRA]A4+	Oct-31-23	[ICRA]A4; Rating watch with developing implications	Mar-14-23	[ICRA]A4	Apr-22-21	[ICRA]A3(CE)
								Dec-29-22	[ICRA]A4		
								Jul-28-22	[ICRA]A4+ (CE)		

\* amount outstanding against the same as on March 31, 2024 is Rs. 27.7 crore

## Complexity level of the rated instruments

Instrument	Complexity indicator
Term loan	Simple
Working capital limits	Simple
Fund based/ Non-fund based working capital	Very Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

**Annexure I: Instrument details**

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Term loans	FY2020	9.55% - 11.5%	FY2027	34.60	[ICRA]BB+(Stable); withdrawn
NA	Fund based – Working capital limits	-	9.55%	--	40.00	[ICRA]BB+(Stable); withdrawn
NA	Fund based/ non-fund based	-	9.55%	--	(30.00)	[ICRA]A4+; withdrawn

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

**Annexure II: List of entities considered for consolidated analysis – Not Applicable**

## ANALYST CONTACTS

**Shamsher Dewan**  
+91 124 4545 328  
[shamsherd@icraindia.com](mailto:shamsherd@icraindia.com)

**Kinjal Shah**  
+91 22 6114 3442  
[kinjal.shah@icraindia.com](mailto:kinjal.shah@icraindia.com)

**Mythri Macherla**  
+91 22 6114 3435  
[mythri.macherla@icraindia.com](mailto:mythri.macherla@icraindia.com)

**Nishant Misra**  
+91 124 4545 862  
[nishant.misra@icraindia.com](mailto:nishant.misra@icraindia.com)

## RELATIONSHIP CONTACT

**L. Shivakumar**  
+91 22 6114 3406  
[shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**  
Tel: +91 124 4545 860  
[communications@icraindia.com](mailto:communications@icraindia.com)

## HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)  
[info@icraindia.com](mailto:info@icraindia.com)

## ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited




### Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



### Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.